SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors used off-label to mimic exercise-induced metabolic effects and support mitochondrial health. Users typically run daily doses ranging from 100 µg to 50 mg, with 500 µg being the most common community protocol, while clinician-tier guidance suggests 1.5 mg twice daily for six to eight weeks. The primary tradeoff is that the evidence base for this compound remains thin, as all human use is off-label and exploratory indications lack published trial results. While sleep and dream changes are occasionally reported, injection-site reactions and gastrointestinal issues have not been a consistent theme.
Data last updated
Measured on 3 of 6 axes
Evidence shape
No registered clinical trials extracted for SLU-PP-332 yet. Off-label / exploratory data exists for 1 additional indication (Preclinical / mechanistic research).
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 22 out-of-stock offers not shown
How SLU-PP-332 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
In the single source consulted for this tier, the dose is 1.5 mg taken orally twice daily, with no cycling protocol reported.
Most of the community clusters around 500 mcg, taken orally once daily, though a smaller group doses twice daily at the same amount. The dose range reported is wide — from 100 mcg up to 50 mg — and a large share of reporters didn't specify a schedule.